In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has aggressively blocked competition for it.
Drug With a 30-Year Monopoly Is Target of State-Level Push to Curb Prices
Written by
in
Antitrust Laws and Competition Issues, Colorado, Drugs (Pharmaceuticals), Enbrel (Drug), Food and Drug Administration, Generic Brands and Products, Health Insurance and Managed Care, Insurance, Inventions and Patents, Law and Legislation, Prices (Fares, Fees and Rates), Regulation and Deregulation of Industry, Sandoz International GmbH, State Legislatures